Acute coronary syndrome
270 results
101 - 200
ED chest pain protocol is safe and efficient- No reduction in postdischarge medication errors after pharmacist-led intervention
- Routine stress testing after negative biomarker testing seldom helpful
- Two-hour protocol identifies patients at low risk of ACS
- Better medication adherence with intervention; clinical outcomes unchanged
- Pain severity does not predict outcomes with AMI
- Flu vaccine reduces risk of adverse CV events in high-risk patients
Dyspepsia - Early invasive therapy better for non-ST ACS
- Concomitant use of clopidogrel and a PPI may increase risk of adverse CHD outcomes
- Apixaban increases bleeding with no benefit in high-risk patients with ACS
Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes: Cochrane systematic review- ACC/AHA guidelines on dual antiplatelet therapy
- Bivalirudin = abciximab + heparin for non-STEMI
- CCTA reduces need for hospitalization in low to moderate risk patients in ED
- Fondaparinux for acute coronary syndromes
- In low-risk patients with ACS, noninvasive testing adds little to clinical evaluation
- Antithrombotic agents in primary health care
- For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
- In ACS, 5 yrs of invasive tx decreases MI but not all cause mortality (FRISC-II)
- Platelet-function testing doesn't improve outcomes in elderly patients with stents after ACS
- ACS risk similar with normal ECG performed during presence or absence of chest pain
- Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
- Evacetrapib increases HDL but does nothing for patient-oriented outcomes
- Interpretation of adult ECG
- Faster discharge but more downstream testing with use of CCTA in ED
- Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
- Low-dose rivaroxaban improves outcomes in patients with ACS (ATLAS)
- Accelerated protocol identifies chest pain patients at low risk for major cardiac events
- Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes: Cochrane systematic review
- ACC/AHA guideline for the management of patients with chronic coronary disease
- Exercise stress test
- Intensive lipid lowering reduces mortality following ACS
- Low HS-troponin I accurate in identifying patients at low risk of cardiac events
- Treatment of a near-drowning person
- Fewer major cardiac events with routine percutaneous coronary intervention in patients undergoing transcatheter aortic-valve implantation (NOTION-3)
- High-sensitivity troponin I of less than 5 ng/L has negative predictive value of 99.9% for cardiac death at 1 year
- Clinical decision rules for evaluating adults with chest pain in primary care are limited in number and utility — stay tuned
- Intensive versus moderate statin therapy
- Restrictive transfusion strategy is best for hospitalized patients
- Small study finds recurrent spontaneous coronary artery dissection risk not associated with subsequent pregnancy
- Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes
- Intensive BP control modestly decreased the likelihood of a broad composite of CV events, but with methodologic limitations
- Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events
- Clopidogrel plus aspirin vs aspirin alone for preventing cardiovascular events
- Echocardiography as an outpatient procedure
- Clopidogrel monotherapy more effective than aspirin to prevent coronary events after PCI with drug-eluting stents (HOST-EXAM)
- Percutaneous coronary intervention does not improve outcomes for patients with ischemic heart disease and LVEF of less than 35%
- Coronary sinus-reducing device improves symptoms for patients with refractory angina
- Similar outcomes after PCI in hospitals with or without on-site cardiac surgery (CPORT-E)
- Overuse alert: treat-to-target LDL strategy of statin dosing is noninferior to high-intensity dosing
- For atrial fibrillation with stable coronary artery disease, edoxaban alone prevents more bad outcomes than edoxaban plus an antiplatelet agent
- Drug treatment for hypertension
- Ticagrelor (Brilinta) is no better than aspirin—and may be worse—for adults after CABG
- Early invasive strategy does not reduce mortality for moderate to severe ischemic heart disease after 5.8 years (ISCHEMIA-EXTEND)
- B vitamins, fish oil do not prevent CV events
- Adding CCTA to chest pain assessment reduces likelihood of nonfatal MI (SCOT-HEART)
- Corticosteroids for the treatment of Kawasaki disease in children
- Systemic lupus erythematosus (SLE)
- Dyspnoea
- Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
- Traditional approach to pretest probability of heart disease overestimates risk
- Pioglitazone does not increase cardiovascular events (PROactive)
- 6-month clopidogrel better than 24 after stent placement (PRODIGY)
- Little if any benefit to early invasive strategy for stable angina and at least moderate reversible ischemia (ISCHEMIA trial)
- High-sensitivity troponin safely reduces admissions and duration of stay in the emergency department
- Less is more when it comes to blood transfusions